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Abstract 
The intestinal epithelium with its barrier function controls the antigen trafficking from the intestinal 
lumen to the submucosa. Zonulin, a precursor of haptoglobin-2, plays a key role in maintaining the 
homeostasis of the intestinal mucosa through the regulation of tight junctions, cell-cell junctions 
responsible of the influx of dietary and microbial antigens via paracellular route of intestinal 
absorption. Several studies have observed an association between zonulin levels and alteration of 
intestinal permeability. It is assumed that in genetically predisposed individuals, an altered intestinal 
permeability may induce an increased exposure to luminal antigens with consequent loss of immune 
tolerance, thus leading to the development and progression of various chronic inflammatory disorders. 
Here, we review the mechanism of  intestinal permeability regulation by zonulin and the related 
physiopathological implications.   
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The intestinal mucosal barrier is a heterogeneous entity composed of physical, biochemical, and 
immune elements elaborated by the intestinal mucosa. The intestinal barrier has a dual role: on one 
hand, limits the contact with pathogens and antigens present in the intestinal lumen, and on the other 
hand, allows the absorption of the nutrients introduced by the diet, covering the fundamental role of 
homeostasis regulator of the intestinal mucosa.1 
 
The intestinal barrier 
The mucus layer 
The first element that forms the intestinal barrier is the mucus layer, which covers the entire cell 
surface and has a protective role against the pathogens of the lumen, mechanical insults and proteolytic 
enzymes. In addition to the protective action, the mucus keeps the mucosa hydrated and lubricated.2, 3 
The mucus is made up of proteins, carbohydrates, lipids and water, but to maintain an intact and stable 
layer, mucins, a family of glycoproteins, are essential. The mucins are divided into two types: the 
mucins secreted in the mucus, whose gene is found on chromosome 11p15.5 (MUC2, MUC5AC, 
MUC5B, MUC6 and MUC19) and the mucins adherent to protein receptors expressed on the cell 
surface (MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13, MUC15, MUC16 and MUC17).4, 5 The 
principal mucin of the intestinal mucous layer is MUC2 and is secreted by intestinal goblet cells.6, 7 
The adherent mucus layer in vivo is continuous throughout the gastrointestinal tract and ranges 
in thickness from 300 µm in the stomach and 700 µm in the intestine. The lower layer is densely 
adherent to the epithelium, sterile in healthy subjects. Instead, the surface layer is less adherent, and 
colonized by bacteria. A smaller portion of mucus is also present in the intestinal crypts and is secreted 
directly by the Paneth cells together with antibacterial proteins, the defensins.2 
Numerous studies have been carried out on the role of MUC2. In a study performed by Van der 
Sluis et al.,8 MUC2- / - knockout mice were compared with MUC 2+/- heterozygous mice exposed to 
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dextran sodium sulfate, a factor inducing colitis. The results showed that knockout mice developed 
colitis in 5 weeks, showing clinical symptoms and microscopic signs of inflammation compared to 
heterozygous mice, thus affirming that the absence of MUC2 induces colitis development. Another 
study by Johansson et al.9 demonstrated that in MUC2 knockout mice, the epithelial cells are in direct 
contact with the lumen bacteria and that these can penetrate into the crypts and also within the 
epithelial cells. 
The transcription of mucins is a process that requires a lot of energy and is finely regulated; the 
genes of secreted mucins and surface mucins are both constitutively expressed and inducible by various 
factors.2 The microbiota can be considered the first regulator of the expression of such genes: the 
bacteria present in the intestinal lumen can activate different intracellular signaling pathways that reach 
the nucleus and, through intranuclear mediators, modify gene expression, determining the transcription 
of a specific subclass of mucins.6 Another trigger capable of altering the expression of mucins is the 
inflammation: inflammatory mediators such as cytokines, oxidizing agents, proteases act on different 
signaling pathways resulting in changes in the conformation of the mucus and in the glycosylation of 
MUC2, as shown by several studies performed on intestinal cell cultures.10 Other stimuli that interact in 
this fine regulatory system are growth factors, lipids, hormones and nervous stimuli. 
In addition to the mucins, in the mucous layer are present: the fc-gamma binding protein 
(Fcgbp), which is supposed to have the role of stabilizing the network of MUC2,11 the trefoil factor 3 
(TTF3), which has been linked to protection mucosa and repair processes,12 and the phospholipid 
phosphatidylcholine (PC) which, through the interaction with mucins, can generate a spatial 
rearrangement in which the PC fatty acids move towards the intestinal lumen, generating one 
hydrophobic protective layer on the outer surface of the mucus.13 The elements listed up to now give 
the mucous layer the role of mechanical protection, and keep the lumen bacteria confined in the outer 
layer. 
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The mucous barrier also acts as a chemical barrier to the pathogens of the lumen, preventing 
damage to the epithelial cells, maintaining their regular growth.14 The intestinal lumen include a 
complex community of pathogens that in physiological conditions lives in symbiosis with our 
organism, supplying nutrients and stimulating the maturation of the immune system. The antimicrobial 
function of mucus was first studied by Meyer-Hoffert et al. in murine models.15 In human beings, 
several studies have confirmed the antibacterial action of mucus towards Gram negative, Gram positive 
but also towards Candida albicans. Several peptides and proteins such as defensins, caltelidicins LL-
37, ubiquitin and members of the histone family have been identified in rectal mucus extracts.16 These 
studies showed that the binding of peptides and antibacterial proteins to mucus and mucins does not 
abolish antimicrobial activity, and that these bonds are at least partly reversible. The bonds are 
characterized by the electrostatic interaction between negative charges of the mucins and positive 
charges of the antimicrobial peptides. In physiological conditions, the microbiota itself interacts with 
immunity receptors located on Paneth cells, triggering the secretion of antimicrobial factors such as 
defensins.17 In fact, an important role in the reaction to lumen pathogens is played by innate immunity 
and in particular by class A immunoglobulins (IgA),18 which are secreted into the mucus and prevent 
the passage of pathogens in the deeper layers.  
 
The epithelial layer 
The intestinal epithelium is constituted by a single cell layer that forms the luminal surface of both the 
small and large intestine of the gastrointestinal tract, representing a further impediment to the passage 
of harmful molecules from the intestinal lumen.19 The intestinal epithelium is a selective and permeable 
barrier: it allows the passage of water, electrolytes and nutrients from diet but prevents the passage of 
microorganisms and toxins.20 To allow this filter function, epithelial cells are closely connected by 
different protein complexes: the tight junctions, the adherent junctions, and the desmosomes. These 
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intercellular connections are necessary for the mechanical cohesion of the cells, to define the boundary 
between the apical and basolateral region of the membrane, and also for the regulation of the 
permeability of the paracellular transport pathway.21 
The epithelium of the small intestine is characterized by the presence of a large number of 
protrusions, villi and microvilli, which greatly increase the absorbent surface of this tract, and between 
the villi, lie the crypts of Lieberkuhn, which are invaginations rich in glands. On the contrary, the 
epithelium of the large intestine has a smaller surface due to the absence of this structural 
organization.22 The predominant cell population of the intestinal epithelium is represented by the 
enterocytes responsible for nutrients absorption, followed by goblet cells, enteroendocrine cells and 
Paneth cells. The enteroendocrine cells secrete peptide hormones involved in cell-cell tropism, tissue 
repair, angiogenesis and cell differentiation along the axis of crypts and villi. Paneth cells contain 
secretory granules which contain a large number of antimicrobial substances such as lysozyme, 
phospholipase A2, defensins. Paneth cells are long-lived cells and are normally confined to the small 
intestine, at the base of the crypts.23 
In addition to these cellular populations, in the epithelial layer, especially of the small intestine, 
there is an epithelium responsible for the uptake of intestinal antigens, the follicole-associated 
epithelium (FAE). This epithelium defines the Peyer’s patches, located in the lamina propria and in the 
submucosa, where the M cells are present, which are part of the gut-associated lymphoid tissue 
(GALT), that phagocyte and transport the bacterial antigens to the dendritic cells, which in turn present 
them to the mesenteric lymph nodes.24-26  
Epithelial homeostasis is maintained by the balance between cell proliferation and apoptosis 
and is fundamental for the barrier function. The regulators of this fine balance are transforming growth 
factor (TGF)-α, which stimulates cell proliferation, TGF-β, which inhibits it, and the Wnt/β catenin 
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signaling pathway.27 Fevr et al. showed that the absence of β-catenin in such a signaling pathway leads 
to an altered stem cell maturation and a dysregulation of intestinal homeostasis.28 
Epithelial cells actively participate in defense mechanisms against pathogens and show on their 
surface Pattern Recognition Receptors (PPRs), which have specific binding domains, to which bacteria 
bind and trigger intracellular signal cascades that lead to the release of cytokines, chemokines and 
antibacterial peptides. The two most studied families of PPRs are the nod-like receptors (NLRs) and the 
toll-like receptors (TLRs). These receptors also seem to be involved in the tolerance of the mucosa 
towards gut microbiota.29 
 
Transport through the intestinal barrier 
Transcellular and paracellular pathways 
The movement of molecules, solutes and ions across the intestinal barrier occurs through two ways: the 
transcellular and the paracellular pathway (Figure 1). The former is the main route for nutrient 
absorption by means of channels and transporters, which are selective in terms of charge and size of the 
molecules, and are positioned on the apical and lateral side of the cell membrane.30 The latter is less 
selective; occurs through the intracellular spaces of intestinal cells, which are closely related to each 
other, and it is a passive process in which the molecules cross the barrier by diffusion, electro-diffusion 
and osmosis according to the gradient generated by the transcellular pathway.31 The paracellular 
pathway is regulated by an apical protein complex formed by tight junction, adherent junctions and 
desmosomes. Adherent junctions and desmosomes form strong bonds between epithelial cells and 
allow intercellular communication, but do not regulate paracellular permeability. The tight junctions 
instead surround the apical portion of the epithelial cells and regulate the paracellular permeability of 
solutes. In this sense, tight junctions represent both a barrier for harmful molecules and a selective 
passage of solutes and water.30, 32 
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Tight junctions and paracellular pathway 
The tight junctions are multiprotein complexes that include four families of transmembrane proteins: 
occludin, claudin, junctional adhesion molecules (JAMs) and tricellulin.33 The intracellular domain of 
these proteins interacts with cytosolic proteins, the zonula occludens (ZO) proteins, which anchor the 
transmembrane proteins to the actin cytoskeleton. The interaction between the tight junctions and the 
actin cytoskeleton is fundamental to maintain the tight junction structure, allowing regulation of the 
paracellular pathway. Actin contraction and tension depends on the myosin light chain, which is 
phosphorylated and therefore activated by kinases such as MLC-kinase and Rho-associated kinase, 
determining the opening of the paracellular pathway.34, 35 
The c-terminal domain of occludins interacts with several intracellular proteins such as the ZO 
proteins, which connect them to the cytoskeleton. The role of occludin is not yet fully understood but 
studies on animal models indicated that they plays a crucial role in the structure of tight junctions and 
in the permeability of the intestinal epithelium, especially towards large molecules. In healthy 
epithelium, occludins are phosphorylated on threonine serine residues, and this phosphorylation allows 
to maintain the tight junction assembled.36 
Claudins are a protein family with at least 24 members in humans and mice; each isoform is 
selectively expressed in tissues and cells. As for occludins, some isoforms are phosphorylated, and this 
regulation mechanism is useful for maintaining permeability. The extracellular portion of the claudins 
forms homophilic or heterophilic bonds with adjacent cells, preventing or facilitating the passage of 
molecules.37, 38 Sonoda et al. demonstrated that the Clostridium perfringes enterotoxin binds to claudin 
3 and to claudin 4, causing the alteration of tight junctions, and thus an alteration of intestinal 
permeability function.39 
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JAM family belongs to the Ig superfamily; JAMs are characterized by two extracellular 
domains, a trans-membrane domain and a c-terminal intracellular domain. The proteins belonging to 
this family are expressed in various tissues, in intestinal epithelial cells JAM-A and JAM-4 are 
involved in the regulation of tight junctions.40 A recent study showed that JAM-A knockout mice have 
greater dextran permeability and increased myeloperoxidase activity, compared to wild type mice. In 
addition, the inflammation induced by dextran sodium sulfate was more severe in this group of mice.41 
Tricellulin is a trans-membrane protein with four binding domains, two extracellular and two 
cytoplasmic.42 This protein plays an important role in the regulation of the epithelial barrier formed by 
the tight junctions, both in tricellular and bicellular junctions. Krug et al. observed that tricellulin forms 
a barrier for macromolecules in tricellular junctions and for all solutes in bicellular junctions.43 
The proteins of the family ZO includes ZO-1, ZO-2, ZO-3, intracellular multidomain proteins 
that are part of the superfamily of the associated guanylate kinase and possess an inactive enzymatic 
guanylate-kinase like domain. These proteins bind to numerous tight junction proteins at the level of 
the c-terminal portion, while at the n-terminal side they bind to actin microfilaments, via proteins 
associated with the cytoskeleton.44-46  
The opening of the tight junctions occurs in response to numerous stimuli: diet, humoral 
stimuli, neuronal, inflammatory markers, mast cell products and a variety of pathways that can be 
target of bacteria and viruses.47 In vivo and in vitro have shown that the pro-inflammatory cytokines 
tumor necrosis factor (TNF)-α and interleukin (IL)-13 can regulate this type of permeability, through 2 
different pathways: a "pore pathway", more selective and based on molecules charge and size, and a 
"leak pathway", characterized by a lower selectivity. IL-13 increases the pore pathway leading to an 
increased expression of claudin 2,48 while TNF-α increases the leak pathway via a rapid mechanism of 
reorganization of the tight junction involving actin microfilaments.49, 50 
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Zonulin and tight junctions 
The discovery of the zonula occludens toxin (Zot), produced by Vibrio cholera, that damages the tight 
junction mechanism, has shed light on the mechanism involved in the modulation of the paracellular 
pathway. Fasano et al. showed that the terminal COOH portion of Zot binds to the receptor activating 
the proteinases 2 (PAR2), and this binding induces the activation of the intracellular signal of kinase c 
proteins (PKC) activation that in turns induces actin microfilaments polymerization and reversible 
opening of tight juncions.51-53 These data suggested that Zot regulates tight junctions in a quick and 
reversible way; it has been hypothesized that Zot may mimic the effect of an endogenous modulator, 
both from a functional and an immunological point of view. The combination of purified anti-zot 
antibodies and the use of the Ussin chamber assay allowed to identify a human Zot homologue called 
zonulin.54 
Zonulin is a 47-kDa protein, identified as pre-haptoglobin-2,55 the inactive precursor of 
haptoglobin-2. Haptoglobin-2, together with haptoglobin-1, is one of the two variants of human 
haptoglobins, which are plasma heterodimeric glycoproteins composed of α- and β-polypeptide chains 
that are covalently associated by disulfide bonds. The role of haptoglobins is to bind hemoglobin, 
forming stable complexes, to prevent oxidative tissue damage induced by free hemoglobin. In contrast, 
no biological activity was known for pre-haptoglobin-2 so far. 56 Structural analysis of zonulin protein 
chains pointed out similarities with the structure of different growth factors. Like zonulin, growth 
factors are also able to alter the integrity of tight junctions.57 Zonulin by binding to PAR2 activates the 
epidermal growth factor receptor (EGFR) and causes the activation of an intracellular pathway that 
determines the activation of PKC-α, that in turn catalyzes the phosphorylation of target proteins, such 
as ZO-1 and myosin 1c, and the polymerization of actin. Subsequently, the rearrangement of actin 
microfilaments leads to the displacement tight junction proteins. The junctional complex returns to its 
initial form when the binding of zonulin with the receptor ceases.56 
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Role of zonulin in altered intestinal permeability 
The alteration of intestinal permeability, secondary to tight junctions derangement, has been 
investigated as a key feature  in the etiopathogenesis of various diseases.57 In particular, in diseases 
with an autoimmune disorder, such as celiac disease (CD), type 1 diabetes (T1D) and multiple 
sclerosis, it has been showed that deranged tight junctions allow the passage of antigens from the 
intestinal lumen, facilitating contact with the immune system and thus triggering the immune response. 
It is commonly accepted that both the interaction with environmental factors and the genetic 
predisposition determine the aberrant immune response that preludes the onset of these diseases. Less 
than 10% of genetically predisposed subjects develop the disease, demonstrating the fundamental role 
of environmental factors.58 The antigens that pass through the intestinal barrier via paracellular 
pathway, interacts with different mediators of the immune response, such as antigen-presenting-cells 
(APCs), T and B lymphocytes.59 In genetically predisposed individuals, when the passage through the 
paracellular pathway of luminal antigens is increased, the immune system can lose the tolerance 
towards non-self-antigens, triggering the multiorgan process leading to systemic diseases.60 
 
Celiac disease 
CD is a unique model of disease with a relevant autoimmune component due to the knowledge 
acquired to date regarding its etiology: genetic predisposition is due to the expression of human 
leukocyte antigen (HLA) genes, with a specific autoimmune response to transglutaminases, and gliadin 
(a prolamin component of gluten) is the known environmental trigger. The interaction between the 
HLA genes and gluten determines the characteristic intestinal damage of CD, which in physiological 
conditions is prevented by functioning tight junctions.61 
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In the early phases of the disease, exposure to gliadin induces an increased zonulin release 
determining the opening of the tight junctions, and thus increasing the passage of antigens to the 
submucosa, through the paracellular pathway.62 The following chain of events has been hypothesized: 
after ingestion of gluten, gliadin interacts with the mucosa of the small intestine causing the release of 
IL-8 from enterocytes, which recalls neutrophils in the lamina propria. At the same time, gliadin 
peptides via MYd-88 induce the release of zonulin, which allows the passage of gliadin into the 
submucosa,63 and the interaction with macrophages, which induce the release of pro-inflammatory 
cytokines such as TNF and intereferon (IFN)-γ. The presence of TNF and IFN-γ supports and increases 
the mechanism triggered by zonulin of altered intestinal permeability with a further increase in the 
passage of antigens.64 
In genetically predisposed subjects, this mechanism leads to an immune-mediated damage to 
the intestinal mucosa, typical of CD. With the removal of gluten from the diet, the levels of zonulin 
decrease, the intestine regains the barrier function and the antibody titers normalize, the autoimmune 
process turns off and the intestinal damage is completely repaired.62 
 
Type 1 diabetes 
Several studies have shown that the alteration of intestinal permeability is an early events associated to 
the development of T1D and its complications.65 Studies on animal models supporting the hypothesis 
of causal relationship between altered intestinal permeability and disease onset have shown that the 
alteration of intestinal barrier is present, and precedes both histological manifestations and symptoms 
development.66 The study conducted by Watts et al. investigated the expression of zonulin in 
BioBreeding diabetes prone (BBDP) mice compared to wild type mice. An increase in zonulin levels 
was observed in BBDP mice over time before symptoms onset. Subsequently, a zonulin inhibitor, 
AT1001, which prevents the tight junction from being disassembled, was administered to BBDP mice. 
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Oral administration of AT1001 blocked the formation of autoantibodies and the alteration of intestinal 
permeability due to zonulin, reducing the incidence of T1D by 70%. These data suggested that the 
increased release of zonulin was necessary for the disease onset.67 A study conducted in T1D patients, 
showed that higher zonulin levels were observed in cases compared to healthy controls. In addition, 
authors observed that first-degree relatives of patients with T1D had higher serum zonulin levels 
compared to healthy controls, suggesting that alteration of intestinal permeability due to zonulin is a 
necessary but not sufficient factor for the development of T1D.68 
Recently, it has been suggested an association between  the concomitant presence of anti-glo-3a 
(a globulin present in gluten) antibodies and increased zonulin, and the risk of developing T1D in 
children, opening new perspectives on altered intestinal permeability mediated by zonulin and T1D 
onset.69 
 
Non-alcoholic fatty liver disease 
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common chronic hepatitis in 
Western countries and comprises a disease spectrum that ranges from simple hepatic steatosis (NAFL) 
to  non-alcoholic steatohepatitis (NASH).69, 70 The natural history comprise the characteristic features 
of chronic liver damage, with fibrosis that overtime may progress to cirrhosis and its complications.71-73  
 There is growing evidence that alterations of gut microbiota and impairment of intestinal barrier 
integrity may play a role in NAFLD pathogenesis and disease progression.74, 75 Pacifico et al. 
investigated the potential association of serum zonulin levels with the stage of liver disease in obese 
children with biopsy-proven NAFLD and observed that zonulin values were significantly higher in 
obese subjects with NAFLD that in those without (4.23 [3.18-5.89] ng/mL vs. 3.31 [2.05-4.63], 
p<0.01).76 In addition, zonulin was correlated with the degree of steatosis (r=0.372, p<0.05) but not 
with lobular inflammation, ballooning and presence of NASH. Possibly, obesity may represent a 
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confounding factor, considering that some reports suggested a relationship between increased zonulin 
levels and higher body mass index (BMI).77, 78 Another study by Hendy et al. showed that serum 
zonulin levels were higher in non-obese adult NAFLD subjects compared to controls; moreover, 
zonulin levels were different among patients with NAFL compared to those with NASH (7.60 ± 0.91 
ng/mL vs. 4.91 ± 0.46, p<0.001, respectively) and were associated to elevated inflammatory markers.79 
In our experience, we observed significantly higher zonulin levels in NAFLD patients 
compared to healthy subjects (42.7 ng/mL vs. 8.6 ng/mL, p<0.001) (Figure 2), but we did not observed 
any differences between patients with NAFL and those with NASH (p=0.879). 
 
Autism spectrum disorder 
A correlation between autism spectrum disorders (ASDs) and gastrointestinal issues have been 
increasingly reported.80 To date, ASD etiology is still unknown; however, both genetic and 
environmental factors are likely to be implied.81 According to the leaky gut hypothesis, the increased 
permeability of intestinal mucosa may allow antigens from diet to pass into blood and affecting central 
nervous system through neuroactive peptides.82, 83 Despite, available data in support of this hypothesis 
are still conflicting,84-86 a recent study reported higher serum zonulin levels in patients with ASD 
(122.3 ± 98.46 ng/mL) compared to healthy controls (41.89 ± 45.83 ng/mL); furthermore, zonulin 
levels were correlated with childhood autism rating scale (r=0.532, p<0.001).87 Consistently, Fiorentino 
et al. observed that patients with ASD had reduced expression of structural proteins involved in tight 
junction complex compared to healthy controls.88 Taken together, these observations foster additional 
studies aiming at elucidate the role of zonulin in influencing gut-brain axis in patients with ASD. 
 
Inflammatory bowel diseases 
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Inflammatory bowel diseases (IBD) are chronic heterogeneous disorders of the bowel resulting from 
environmental precipitants in genetically susceptible individuals and are distinguished in two main 
phenotypes, Crohn's disease and ulcerative colitis.89-91 Pathogenesis of IBD is multifactorial with 
immunological, genetic, microbial and environmental factors contributing to the onset of the disease.92, 
93 Since intestinal epithelial barrier plays a key role in regulating the interaction between antigens from 
the intestinal lumen and the mucosal immune system, intestinal permeability may represents an 
additional piece of this intricate puzzle.94, 95 Studies from the animal model showed that impaired 
intestinal permeability represents an early event preceding disease onset; indeed, the passage of non-
self-antigens in the lamina propria may trigger the immune response mediated by cytokines such as 
IFN-γ and TNF-α which in turn may perpetuate the increased intestinal permeability, starting a vicious 
circle.96  
Recently, we investigated serum zonulin levels in patients with IBD in comparison to healthy 
subjects and we observed that zonulin concentration was higher in the former group (34.5 [26.5-43.9] 
ng/mL vs. 8.6 [6.5-12.0] ng/mL, p<0.001) showing an area under the curve of 0.98 for the 
discrimination between IBD patients and healthy controls.97 To note, no difference in serum zonulin 
concentration was observed between patients with Crohn’s disease and those with ulcerative colitis 
(p=0.074) (Figure 3). In addition, we observed an inverse correlation between serum zonulin 
concentration and disease duration (rs=-0.30, p=0.001);
97 this finding is consistent with the concept that 
altered intestinal permeability is present in IBD patients from the beginning of the disease, being this 
condition a necessary but not sufficient pathogenic element for disease development. 
To date, only few studies investigated serum and fecal zonulin concentration in patients with 
IBD showing conflicting results. Malickova et al. reported higher serum and fecal zonulin values in 
patients with active Crohn’s disease compared to ulcerative colitis.98 Our results do not support this 
observation; moreover, we did not find any correlation between serum and fecal zonulin concentration 
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(rs=0.15, p=0.394).
97 In agreement with our findings, also Ohlsson et al. reported no correlation 
between zonulin concentration in serum and feces.99 Finally, Frin et al. investigated fecal zonulin as a 
potential predictor of response to infliximab therapy in patients with UC, but a low accuracy was 
observed.100 Likely, the measurement of zonulin in serum rather than in stool may be of greater clinical 
interest. 
 
 Conclusions 
Zonulin is involved in the functional regulation of intestinal barrier and alterations in zonulin 
expression have been described in different clinical settings. A part from the above discussed diseases, 
several other diseases have been linked to the zonulin pathway and to the increase passage of molecules 
through the paracellular pathway including asthma, multiple sclerosis, glioma,  ankylosing spondylitis, 
rheumatoid arthritis and coronary artery disease.56, 101-104 
In the last decades, different diagnostic methods have been proposed for the assessment of 
intestinal barrier integrity, including lactulose mannitol ratio test and 51Cr-labeled 
ethylenediaminetetraacetic acid (51Cr-EDTA) absorption test.105, 106 However, these tests have some 
limitations: the former is unable to assess the permeability of the colon since both lactulose and 
mannitol are degraded by the local microbiota, while the latter make use of a radioactive molecule. 
Conversely, the measurement of zonulin levels either in serum or in stool, may represent an alternative 
non-invasive tool to investigate the integrity of intestinal barrier.  
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Figure 1. Transport of molecules through the intestinal barrier. 
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Figure 2. Comparison of serum zonulin concentration between healthy control and patients with 
NAFLD. 
 
HC, healthy controls; NAFLD, non-alcoholic fatty liver disease.  
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Figure 3. Comparison of serum zonulin concentration in healthy control and patients with Crohn’s 
disease and ulcerative colitis. 
 
CD, Crohn’s disease; HC, healthy controls; UC, ulcerative colitis. 
 
